Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis-Reference-Cited by-同舟云学术

Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis

Published:2020-07 Issue:8 Volume:18 Page:1760-1768.e1
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Ma Christopher^ORCID,Sandborn William J.,D’Haens Geert R.,Zou Guangyong,Stitt Larry W.,Singh Siddharth,Ananthakrishnan Ashwin N.,Dulai Parambir S.,Khanna Reena,Jairath Vipul,Feagan Brian G.

Funder

Clinician Fellowship from the Canadian Institutes of Health Research

Crohn's and Colitis Canada

Canadian Association of Gastroenterology

Tillotts Pharma

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference21 articles.

1. Ulcerative colitis;Ungaro;Lancet,2017

2. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target;Peyrin-Biroulet;Am J Gastroenterol,2015

3. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis;Shah;Clin Gastroenterol Hepatol,2016

4. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus;Bressler;Gastroenterology,2015

5. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development;Reinisch;Clin Gastroenterol Hepatol,2019

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. To STRIDE or not to STRIDE: a critique of “treat to target” in ulcerative colitis;Expert Review of Gastroenterology & Hepatology;2024-08-28

2. The Contribution of Genetic and Epigenetic Factors: An Emerging Concept in the Assessment and Prognosis of Inflammatory Bowel Diseases;International Journal of Molecular Sciences;2024-08-01

3. Evaluación de la sensibilidad y especificidad de la sigmoidoscopia en comparación con la colonoscopia en la detección de actividad inflamatoria intestinal en el seguimiento de pacientes con colitis ulcerosa;Gastroenterología y Hepatología;2024-07

4. Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD;Alimentary Pharmacology & Therapeutics;2024-05-10

5. Differences Between the 2016 and 2022 Food and Drug Administration Guidance—Implications for Design and Interpretation of Clinical Trials in Ulcerative Colitis;Crohn's & Colitis 360;2024-04-01